Eclipse plans port-access TMR trial:
This article was originally published in Clinica
Eclipse Surgical Technologies is planning a trial of minimally-invasive laser heart revascularisation, following approval from the FDA. Transmyocardial revascularisation (TMR) uses a laser to drill holes in the heart of patients with angina. Until now Eclipse had performed the procedure through a standard surgical chest incision. The development of a steerable fibreoptic laser catheter will allow the procedure to be performed via a 2-4 inch mini-thoracotomy.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.